Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment.	Novartis	Ongoing	ABL001 (Asciminib), Imatinib, Nilotinib, Bosutinib	3	CABL001A2001B	King Faisal Specialist Hospital and Research Center (Riyadh)
Palbociclib Combinations in HR+/HER2- Metastatic Breast Cancer Patients: A Non-Interventional Prospective Study on the Treatment Patterns & Clinical Outcomes in Africa Middle East (PRECIOUS)	pfizer	Ongoing	PALBOCICLIB	4	A5481150	King Fahad Specialist Hospital (Dammam) , King Abdulaziz Medical City NG (Riyadh) , King Khalid University Hospital (Riyadh)
Non-invasive ventilation and dexmedetomidine in critically ill adults: a vanguard pragmatic randomized controlled trial (inDEX trial)	King Abdullah International Medical Research Center (KAIMRC)	Ongoing	dexmedetomidine , Non-invasive ventilation	3	SCT22R/001/01	King Abdulaziz Medical City NG (Riyadh)
A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen	Biogen Idec Research Limited	Ongoing	Nusinersen (Spinraza)	3	232SM302	King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam),King Abdulaziz Medical City NG (Jeddah)
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease	Forma Therapeutics, Inc	Ongoing	FT-4202	2/3	4202-HEM-301	King Khalid University Hospital (Riyadh),Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabia
EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy	Novartis Saudi Limited	Completed	BYL719 / Alpelisib	2	CBYL719C2202	King Fahad Specialist Hospital (Dammam),King Khalid University Hospital (Riyadh)
Multinational Survey-Based Chart Review Study in International Markets to Evaluate the Effectiveness, Safety, and Treatment Patterns of DUPIXENT® (Dupilumab) in Patients with Moderate-to-Severe Atopic Dermatitis	Sanofi-Aventis group	Completed	DUPIXENT® (Dupilumab)	4	DUT0012	Specialized Medical Center (Riyadh),Dr. Erfan & Bagedo General Hospital (Jeddah)
A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE)	Agios Pharmaceuticals, Inc.	Ongoing	Mitapivat	3	AG348-C-017	King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Hospital NG (Al Ahsa)
A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE-T)	Agios Pharmaceuticals, Inc.	Ongoing	Mitapivat	3	AG348-C-018	King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Hospital NG (Al Ahsa)
A Multi-Country Observational Retrospective Study to Evaluate the Prevalence of PD-L1 and its Role in Patients with TNBC Treated with Systemic Therapy (VANESSA)	Hoffmann-La Roche Ltd	Ongoing	N/A	4	MO42921	King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh)